Use of levofloxacin in community-acquired pneumonia

Abstract number: 1134_02_81

Olalla J., Escot I., García-Alegría J.J.

Introduction and objectives:

Community Acquired Pneumonia (CAP) is a prevalent and important disease, with an important consume of resources at Hospitals. Our aim is to study the profile of income patients with CAP diagnosis, the year of introduction of levofloxacin in our centre and compare the length of stay in order to different antibiotics treatments, adjusting the results by Fine's scale.


In our hospital (a second level hospital in Marbella, Spain) all the diagnosis at discharge are codified and included in the hospital database, so, all the diagnosis of CAP between September 2001 and March 2002 were collected, and clinical reports were examined. Demographic data were registered, so were all the parameters affecting Fine classification, antibiotic treatment, intensive care unit (ICU) incomes, deaths and length of stay.


129 cases of CAP were found (86 males, 43 females), with a mean age of 67 years (ys)-CI 95%: 64–70), no difference between gender. 4 patients (pts) were living in a residence. 11 pts (8.5%) had a previous diagnosis of Heart Failure -HF-(mean of age 78 vs 66, p < 0.005) and other 11 pts had Cerebrovascular disease -CVD- (mean of age 80.7 vs 66, p < 0.01), 12 pts had Chronic hepatopathy, 15 –11.5%- any form of cancer, 23–17.8%- pts Chronic renal failure (mean of age 74 vs 66, p = 0.049), 41 pts (32%) Chronic Obstructive Pulmonary Disease (COPD). 3 pts were admitted at ICU and 3 deaths were registered. Blood cultures were collected in 30% of cases, culture of sputum in 21%, Legionella antigen in urine in 13.2%. In according with Fine's classification the patients were stratified in group I (10.9%), II (16.3%), III (22.5%), IV (27.9%) and V (22.5%). In 40% cases corresponding to Fine I and II levofloxacin was used alone, vs 19% in Fine III, IV and V (p=0.021). When length of stay was analysed in patients Fine I and II, the use of levofloxacin was associated with a non significant reduction (MEAN + SE: 5.86 + 2.7 days vs 7.67 + 4.9 days), in people on groups III, IV and V use of levofloxacin do not showed any reduction of length of stay (6.67 + 5.06 days in people using levofloxacin vs 6.11 + 4.5 days). No readmissions in relationship with recurrent CAP was registered.


In our experience, use of levofloxacin is associated with less severe CAP, in which a non significant reduction in length of stay is observed.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Location: Oxford, UK
Presentation type:
Back to top